Eagle Pharmaceuticals, Inc Earning Date (EGRX)

USA |NASDAQ |USD

EGRX Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Feb 28, 2022 Dec 2021 $0.95 $0.56 $0.96
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Feb 28, 2022 Dec 2021 $51.54M $39.85M $49.92M

Eagle Pharmaceuticals, Inc's next earnings date is Monday, Feb 28, 2022 for the fiscal quarter ending Dec 2021.

EGRX Earnings Date & History Chart

EGRX Earnings & Revenue Forecast

EGRX Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 3 $0.95 $0.86 $1.08
Mar 2022 1 $1.12 $1.12 $1.12
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 3 $2.73 $2.60 $2.92
Dec 2022 3 $6.45 $5.37 $7.67

EGRX Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 1 / 1 $1.00 $1.00 $1.10
Mar 2022 1 / 0 $0.91 $0.91 $0.85
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 1 $3.02 $3.02 $3.12
Dec 2022 2 / 0 $5.65 $5.65 $4.69

EGRX Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 3 $51.54M $46.51M $58.60M
Mar 2022 2 $62.70M $62.50M $62.90M
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 3 $181.21M $175.74M $189.20M
Dec 2022 3 $316.75M $285.66M $356.00M

EGRX Earnings Date & Revenue History

EGRX Earnings History

|
Show More
Show More

EGRX Revenue History

|
Show More
Show More

Eagle Pharmaceuticals, Inc Next Earnings Date & Report

EGRX Next Earnings Date & Report Preview: Dec 2021 (FQ)

EGRX's next earnings date is Monday, Feb 28, 2022 for the fiscal quarter ending Dec 31, 2021.

According to 3 analysts, the average EPS estimation for Eagle Pharmaceuticals, Inc's next quarterly earnings is $0.95, with a low EPS estimation of $0.86, and a high estimation of $1.08.

Over the last 1 month, EPS estimates have seen 1 upward revisions and 1 downward. The EPS 1 month trend is $1.00, the last 2 month trend is $1.00, and the 3 month trend is $1.10.

Based on 3 analysts, the average revenue estimation is $51.54M, with a low revenue estimation of $46.51M, and a high estimation of $58.60M.

Eagle Pharmaceuticals, Inc Previous Earnings Dates & Reports

EGRX Previous Earnings Date & Report Recap: Sep 2021 (FQ)

Eagle Pharmaceuticals, Inc's previous earnings date was Nov 9, 2021 for its fiscal quarter ended Sep 30, 2021.

EGRX's earnings per share (EPS) was $0.56, missing the consensus analysts forecast of $0.83 by -32.73%.

The EPS was lower than the previous fiscal quarter (Jun 2021) by -39.78%, and lower than the same period a year before (Sep 2020) by -52.14%.

Revenues were $39.85M, worse than the forecast of $46.40M by -14.11%, down by -17.19% from the previous quarter , and down by -20.18% from the same period last year.

The company reported a net income of $-5.62M.

Free cash flow for the quarter was $1.06M , compared to $8.71M last quarter and $5.43M a year before.

EGRX ended the quarter with $31.74M in total debt, a decrease of -6.40% compared to the previous quarter, and a decrease of -12.17% compared to the same quarter a year before.

EGRX Previous Earnings Date & Report Recap: Dec 2020 (FY)

Eagle Pharmaceuticals, Inc's previous annual earnings date was Mar 2, 2021 for its fiscal year ended Dec 31, 2020.

EGRX's earnings per share (EPS) was $3.54, beating the consensus analysts forecast of $2.43 by 45.68% , and higher than the previous year's EPS (Dec 2019) by 36.68%.

Revenues were $187.80M, worse than the forecast of $191.06M by -1.71%, and down by -4.13% from previous year's revenue.

The company reported a net income of $11.99M, -16.24% lower than the previous year.

Eagle Pharmaceuticals, Inc reported a free cash flow of $48.75M for its fiscal year, compared to $55.21M a year ago.

The company ended the fiscal year with $33.13M in total debt, a decrease of -14.06% compared to the previous year.